Volume 23, Issue 4, Pages e3 (April 2018)

Slides:



Advertisements
Similar presentations
Volume 42, Issue 2, Pages (February 2015)
Advertisements

Volume 5, Issue 1, Pages (January 2009)
Volume 22, Issue 4, Pages e4 (October 2017)
Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice  Inessa Schwab, Anja Lux, Falk Nimmerjahn  Cell.
Community Behavior and Spatial Regulation within a Bacterial Microcolony in Deep Tissue Sites Serves to Protect against Host Attack  Kimberly M. Davis,
Volume 42, Issue 3, Pages (March 2015)
The Requirement for Cyclin D Function in Tumor Maintenance
Volume 45, Issue 1, Pages (July 2016)
Volume 40, Issue 2, Pages (February 2014)
Volume 15, Issue 1, Pages (January 2014)
Volume 18, Issue 5, Pages (May 2010)
Volume 18, Issue 4, Pages (October 2015)
Volume 6, Issue 5, Pages (November 2009)
Volume 11, Issue 6, Pages (June 2012)
Volume 22, Issue 1, Pages (January 2015)
Molecular Therapy - Nucleic Acids
Activation of the Innate Signaling Molecule MAVS by Bunyavirus Infection Upregulates the Adaptor Protein SARM1, Leading to Neuronal Death  Piyali Mukherjee,
DAI/ZBP1/DLM-1 Complexes with RIP3 to Mediate Virus-Induced Programmed Necrosis that Is Targeted by Murine Cytomegalovirus vIRA  Jason W. Upton, William J.
Volume 15, Issue 4, Pages (April 2014)
Volume 6, Issue 4, Pages (October 2009)
Brian Yordy, Norifumi Iijima, Anita Huttner, David Leib, Akiko Iwasaki 
Volume 36, Issue 3, Pages (March 2012)
Volume 17, Issue 5, Pages (May 2015)
Influenza Virus-Induced Glucocorticoids Compromise Innate Host Defense against a Secondary Bacterial Infection  Amanda M. Jamieson, Shuang Yu, Charles.
Volume 31, Issue 1, Pages (July 2009)
Volume 43, Issue 4, Pages (October 2015)
Volume 7, Issue 2, Pages (February 2010)
Volume 38, Issue 2, Pages (February 2013)
Volume 4, Issue 3, Pages (September 2008)
Volume 33, Issue 1, Pages (July 2010)
Volume 22, Issue 1, Pages e7 (July 2017)
Volume 40, Issue 1, Pages (January 2014)
Volume 17, Issue 4, Pages (April 2015)
Volume 48, Issue 4, Pages e4 (April 2018)
Volume 11, Issue 6, Pages (June 2012)
B Cell Receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells  Wei Luo, Florian.
Volume 21, Issue 1, Pages (January 2017)
Volume 42, Issue 2, Pages (February 2015)
Volume 44, Issue 4, Pages (April 2016)
Volume 35, Issue 2, Pages (August 2011)
Volume 13, Issue 4, Pages (April 2013)
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
Volume 30, Issue 2, Pages (February 2009)
Tracking Vibrio cholerae Cell-Cell Interactions during Infection Reveals Bacterial Population Dynamics within Intestinal Microenvironments  Yang Fu, Brian.
Volume 14, Issue 2, Pages (August 2013)
Volume 6, Issue 1, Pages (July 2009)
Volume 37, Issue 5, Pages (November 2012)
Volume 5, Issue 1, Pages (January 2009)
Volume 22, Issue 5, Pages e5 (November 2017)
Volume 18, Issue 6, Pages (December 2015)
Zika Virus Infects Human Placental Macrophages
Volume 43, Issue 5, Pages (November 2015)
Volume 22, Issue 5, Pages e5 (November 2017)
Lukxmi Balathasan, Vera A
Volume 17, Issue 5, Pages (May 2015)
Cellular 5′-3′ mRNA Exonuclease Xrn1 Controls Double-Stranded RNA Accumulation and Anti-Viral Responses  Hannah M. Burgess, Ian Mohr  Cell Host & Microbe 
Cell-Intrinsic IL-27 and gp130 Cytokine Receptor Signaling Regulates Virus-Specific CD4+ T Cell Responses and Viral Control during Chronic Infection 
Volume 37, Issue 5, Pages (November 2012)
Volume 42, Issue 4, Pages (April 2015)
Volume 15, Issue 3, Pages (March 2014)
Volume 17, Issue 5, Pages (October 2016)
Volume 13, Issue 5, Pages (May 2013)
Molecular Therapy - Oncolytics
Volume 26, Issue 4, Pages (April 2018)
Volume 15, Issue 4, Pages (April 2014)
Volume 2, Issue 4, Pages (October 2007)
Volume 21, Issue 3, Pages (March 2017)
Volume 22, Issue 1, Pages (January 2015)
Volume 17, Issue 6, Pages (November 2016)
Volume 26, Issue 6, Pages (June 2007)
Presentation transcript:

Volume 23, Issue 4, Pages 549-556.e3 (April 2018) Small Interfering RNA-Mediated Control of Virus Replication in the CNS Is Therapeutic and Enables Natural Immunity to West Nile Virus  Jagadish Beloor, Nyree Maes, Irfan Ullah, Pradeep Uchil, Andrew Jackson, Erol Fikrig, Sang Kyung Lee, Priti Kumar  Cell Host & Microbe  Volume 23, Issue 4, Pages 549-556.e3 (April 2018) DOI: 10.1016/j.chom.2018.03.001 Copyright © 2018 Elsevier Inc. Terms and Conditions

Cell Host & Microbe 2018 23, 549-556. e3DOI: (10. 1016/j. chom. 2018 Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 1 Intranasal RVG9R-siRNA Elicits Widespread Gene Silencing in the Brain (A) The indicated organs were examined for fluorescence 24 hr after i.n. administration of PBS (mock), and 9R or RVG9R-complexed siFITC. Left: representative fluorescent images overlaid with their bright-field images. Right: cumulative data from three mice depicting mean fluorescence intensities (MFIs) in arbitrary pixel values ± SD. (B) qPCR for SOD1 mRNA in mouse brain regions at 24 hr after the last i.n. treatment with RVG9R-siSOD1 (solid bars) and RVG9R-siNT (open bars). Data are mean percent gene expression (±SD) relative to GAPDH after normalizing with corresponding data of mock-treated cohort. n = 3 mice per treatment per time point. NT, non-targeting. ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001. See also Figure S2. Cell Host & Microbe 2018 23, 549-556.e3DOI: (10.1016/j.chom.2018.03.001) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 2 Intranasal RVG9R-siFvEJW Is Therapeutic for WNV Infection (A) Kaplan-Meier survival curves of C3H mice treated with RVG9R-siRNA formulations at the indicated days p.i. with 100 LD50 WNV. Data are from three experiments with mouse cohorts of at least n = 5 mice per group per treatment. Survival statistics in all test cohorts (except treatment at days 6 and 7) achieved significance by the log-rank test when compared with mock- or siNT-treated mice. siNT, siLuc; siScr, scrambled siRNA for siFvEJW. (B) Mean WNV titers (±SE) per gram of brain tissue at the indicated days p.i. Each data point represents one mouse. The dotted line depicts the assay's limit of detection. ND, not detectable. (C) Representative images of mouse brain tissue sections analyzed by fluorescent immunohistochemistry at day 9 p.i. Scale bar, 30 μm. (D) Graphical presentation of data in (C) depicting MFI of GFAP-positive cells (±SE) and mean numbers of TUNEL-positive cells per high power field (±SE, n = 10) combined from four mice per treatment condition. ∗p ≤ 0.05; ∗∗∗p ≤ 0.001; ∗∗∗∗p ≤ 0.0001. See also Figure S3. Cell Host & Microbe 2018 23, 549-556.e3DOI: (10.1016/j.chom.2018.03.001) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 3 Immune Responses Mediate Recovery in RVG9R-siFvEJW-Treated WNV-Infected Mice (A) Kaplan-Meier survival curves of immunodeficient NSG mice treated intranasally with RVG9R-siFvEJW on days 4 and 5 p.i. with 100 LD50 WNV. n = 6 mice per group. (B) Flow cytometric detection of TFH (CD4+, PD1+, and CXCR5+) and GC B (B220+, Fas+, and GL7+) cells in spleens of RVG9R-siFvEJW-treated C3H mice on day 8 p.i. Left: representative plots. Right: cumulative data with mean values ± SE. Each data point represents one mouse. (C) Serum PRNT90 of mice treated with RVG9R-siFvEJW at the indicated days p.i. with WNV. Horizontal bars depict the geometric mean. ∗∗p ≤ 0.01. (D) Kaplan-Meier survival curves of C3H recipients that received splenocyte populations (with or without immune serum) at day 5 p.i. with WNV from donor RVG9R-siFvEJW-treated mice that survived WNV challenge. n = 3–4 mice per group. See also Figure S3. Cell Host & Microbe 2018 23, 549-556.e3DOI: (10.1016/j.chom.2018.03.001) Copyright © 2018 Elsevier Inc. Terms and Conditions

Figure 4 Intranasal RVG9R-siFvEJW Treatment Induces Long-Lasting Sterilizing Immunity to WNV (A) Experimental timeline for rechallenge studies. (B) Kaplan-Meier survival curves of RVG9R-siFvEJW-treated C3H mice challenged for a second time with 100 LD50 WNV either 1 or 6 months after primary challenge. n = 5–8 mice per group. (C) Serum PRNT90 of C3H mice on day 21 after the second WNV challenge (Post 2°), immunization with H2O2-inactivated WNV (WNVinact), or at 6 months after primary challenge (Pre 2°). Each data point represents one mouse. Horizontal bars are geometric mean values. ns, not significant. (D) Data depicting proportion of mice positive for the specified clinical or virologic parameter. siFvEJW refers to mice treated with i.n. RVG-9R-siFvEJW at days 5 and 6 p.i. a, bPositive for WNV RNA on day 4 or day 8 after challenge. c, d, ePositive for infectious WNV on day 4, 8, or 30 after challenge. nd, not determined. See also Figure S4. Cell Host & Microbe 2018 23, 549-556.e3DOI: (10.1016/j.chom.2018.03.001) Copyright © 2018 Elsevier Inc. Terms and Conditions